News
Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...
Hosted on MSN1mon
Fast-moving Durham startup Tune Therapeutics works to turn off genes that cause diseasesTune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...
Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.
This year, Tune Therapeutics Principal Scientist Brian Cosgrove shared new in vitro and in vivo data, showcasing Tune’s clinically optimized liver-targeting LNP-RNA epi-silencing drug (Tune-401 ...
DURHAM, N.C. & SEATTLE, January 13, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates ...
A new CEO is leading a Durham biotechnology company that recently closed a $175 million funding round.
Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support ...
Tune Therapeutics is pioneering a new therapeutic modality (termed epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results